Avacta Group advances Phase 1 trial of oncology drug candidate AVA6000
Avacta Group plc (AIM: AVCT), a prominent life sciences company, has achieved a significant milestone in its Phase 1 clinical trial for AVA6000, a novel ... Read More
Avacta Group reports promising early results for Phase 1a study of AVA6000
Avacta Group plc (AIM: AVCT), a leading life sciences company dedicated to developing innovative oncology drugs and powerful diagnostics, has announced a crucial milestone in ... Read More